We invite you to join us on May 31st for the Distinguished Scientist Lecture featuring the work of Reisa Sperling, MD, MMSC. Dr. Sperling is the Director of the Harvard Center for Alzheimer's Research and Treatment, Director of Clinical Research for the Memory Disorders Unit at Brigham and Women's Hospital, and Director of the Neuroimaging Program at the Massachusetts Alzheimer's Disease Research Center at Brigham and Women’s Hospital. Her studies concentrates on the early diagnosis and treatment of Alzheimer's disease.
Dr. Sperling is a neurologist focused on the early detection and treatment of Alzheimer’s disease, even before clinical symptoms are evident. Her research uses multi-modality neuroimaging and sensitive cognitive assessments to study the aging brain and the earliest changes associated with Alzheimer’s disease. She chaired the 2011 NIA-Alzheimer’s Association workgroup to develop guidelines for the study of “Preclinical Alzheimer’s disease.” Dr. Sperling leads the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study - a landmark secondary prevention trial in over 1,150 clinically normal older individuals with PET amyloid imaging evidence of early Alzheimer’s disease pathology, and the companion LEARN Study. In recognition of her many accomplishments, Dr. Sperling has been presented with numerous awards including the 2011 Derek Denny-Brown Young Neurological Scholar Award, the 2015 American Academy of Neurology Potamkin Prize, and was named one of the 2017 Most Disruptive Women to Watch in Healthcare.
Location. UPMC Western Psychiatric Hospital Auditorium.
For More Information. Please contact Frances Patrick (Telephone: 412-246-6787; Email: firstname.lastname@example.org)
Learning Objectives. At the conclusion of Dr. Sperling's lecture, attendees will be able to:
Describe the preclinical stage of Alzheimer’s disease and risk of cognitive decline.
Evaluate imaging and biomarker detection of early Alzheimer’s disease.
Assess progress on ongoing Alzheimer prevention trials.